In this 360° Virtual Tour of our Limoges, France site, explore ÌìÃÀÓ°Ôº’s European center of excellence for early-phase clinical biologics formulation development and drug product fill/finish.

PRIMARY SITE CAPABILITY

In this 360° virtual tour, explore ÌìÃÀӰԺ’s Beinheim, France facility which houses Rx and OTC softgel development and manufacturing operations. This site specializes in formulation development and manufacturing solutions of controlled substances, highly potent compounds, and hormones.

PRIMARY SITE CAPABILITY

Softgel Technologies

ÌìÃÀÓ°Ôº has a network of Cell Therapy clinical and commercial manufacturing facilities in the US and Europe. Discover our capabilities for the development and manufacturing of allogeneic and autologous immuno- and stem-cell therapies. Learn about our expertise in both early and late-stage manufacturing as you get a glimpse inside our cell therapy facility in Gosselies.

PRIMARY SITE CAPABILITY

In this 360° Virtual Tour, explore our biggest European softgel development and manufacturing facility in Eberbach, Germany.Ìý With capacity of 12.8 billion softgel capsules per year, it features integrated softgel manufacturing services including coating and packaging simplify supply chain management and deliver products faster to market. The facility can handle highly potent and cytotoxic compounds with our self-contained, separated cytotoxic suite. Within the ÌìÃÀÓ°Ôº network, we offer a broad range of integrated formulation and analytical services to solve your most difficult development and manufacturing challenges.

PRIMARY SITE CAPABILITY

Optiform® Solution Suite

In this video, tour the ÌìÃÀÓ°Ôº Clinical Supply Services facility in Schorndorf, Germany, and explore our innovative and flexible end-to-end clinical supply solutions for Europe and beyond, including packaging, labeling, and storage and distribution services for your oral, biologic, and advanced therapy medicinal products.

PRIMARY SITE CAPABILITY

PRIMARY SITE CAPABILITY

Orally Disintegrating Tablets
Oral Macromolecule Delivery

ÌìÃÀӰԺ’s Swindon, UK facility, located 85 miles west of central London, is the manufacturing center for ÌìÃÀӰԺ’s Zydis® Orally Disintegrating Tablet (ODT) platform.Ìý Equipped with high-speed manufacturing suites, the site produces approximately 1.2B doses per year and supports both Rx and OTC products as well as potent and controlled substances.

With more than 35 products launched in over 60 countries, the Zydis® ODT technology is the world’s best-in-class ODT technology. The Zydis fast-dissolve platform consists of three technologies: Zydis ODT, Zydis Ultra®, and Zydis Bio. Zydis ODT is a unique freeze-dried oral solid dosage form with almost instant oral dispersion, typically less than three seconds, without the need for water. Zydis Ultra technology offers enhanced taste-masking capabilities, increased drug loading, and the potential for functional coating. Zydis Bio technology offers a formulation strategy for oral delivery of peptides, allergens, and viral vaccines.

PRIMARY SITE CAPABILITY

Orally Disintegrating Tablets
Oral Macromolecule Delivery

In this 360° Virtual Tour, explore ÌìÃÀӰԺ’s Schorndorf location, the flagship EU manufacturing location for large scale reliable supply of complex controlled release oral solid dose forms through state-of-the-art fluid bed granulationÌýcapabilities, integrated development, commercial manufacture and packaging.

PRIMARY SITE CAPABILITY

Controlled Release
Commercial Manufacturing

In this 360° Virtual Tour, explore ÌìÃÀӰԺ’s Aprilia facility. This site, located in Europe, is a center of excellence for softgel development and manufacturing for both oral and topical dose forms. This site features innovative technologies for Pharmaceuticals, Over-The-Counter, Nutritional Supplements and Topical Beauty.

PRIMARY SITE CAPABILITY

ÌìÃÀӰԺ’s Schorndorf location is the flagship EU manufacturing location for large scale reliable supply of complex controlled release oral solid dose forms through state-of-the-art fluid bed granulation and hot melt extrusion capabilities, integrated development, commercial manufacture and packaging.

PRIMARY SITE CAPABILITY

Controlled Release
Commercial Manufacturing